ADHD 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 약물 유형별, 유통 채널별, 인구통계학적, 지역별, 부문별 예측(2024-2032년)

The global Attention Deficit Hyperactivity Disorder market size is expected to reach USD 30,568.94 Million by 2032, according to a new study by Polaris Market Research. The report "Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, Non-Stimulants); By Distribution Channel; By Demographics; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The escalating prevalence of Attention Deficit Hyperactivity Disorder significantly propels the market, directly stimulating the demand for diagnostic services, therapeutic interventions, and ongoing management solutions. Heightened awareness among healthcare professionals and the general public regarding ADHD symptoms and their impact on quality of life has led to more frequent and earlier diagnoses. Consequently, this has expanded the market for both pharmaceutical treatments, including stimulants and non-stimulants, and behavioral therapies.

Furthermore, the acknowledgment of ADHD as a chronic condition necessitating long-term management further drives market growth, fostering ongoing research and development of novel and enhanced treatment options. The expanding recognition of ADHD's prevalence among both children and adults broadens the market scope, fueling demand for diverse treatment modalities tailored to different age groups and individual needs.

A number of factors impact the ADHD market, including the rising prevalence of the disorder, increased awareness among physicians and patients, and advancements in diagnostic and treatment methods. However, challenges such as underdiagnosis, rigorous regulatory processes, and high medication costs may impede market growth in the future. The market is highly competitive, with several major pharmaceutical companies leading the way through significant investment in research and development and a wide range of products. These companies are dedicated to creating new and enhanced medications, including stimulant and non-stimulant options, to cater to the varied requirements of patients with ADHD.

Attention Deficit Hyperactivity Disorder Market Report Highlights

The stimulant drug category held the largest market share due to its established effectiveness and quick onset of action in the management of ADHD symptoms.

The hospital pharmacy sector is expected to experience significant growth in the coming years as awareness and diagnosis of ADHD continue to rise. This trend is leading to an increase in the number of patients seeking specialized care and comprehensive management plans, which are typically offered in hospital settings.

In 2023, North America dominated the market due to the high incidence of ADHD diagnoses. This can be attributed to increased awareness and acknowledgment of the disorder among healthcare providers and the general population in the region.

The global key market players include ADVANZ PHARMA, Amneal Pharmaceuticals LLC, Aytu BioPharma, Inc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Lupin, Mallinckrodt, Novartis AG, Noven Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd, Tris Pharma, Inc, Zevra Therapeutics, etc.

Polaris Market Research has segmented the artificial lift market report based on drug type, distribution channel, demographics, and region:

Attention Deficit Hyperactivity Disorder, Drug Type Outlook (Revenue - USD Million, 2019 - 2032)

• Stimulants
• Non-Stimulants

Attention Deficit Hyperactivity Disorder, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

• Retail Pharmacy
• Hospital Pharmacy

Attention Deficit Hyperactivity Disorder, Demographics Outlook (Revenue - USD Million, 2019 - 2032)

• Children (2 to 17 years of age)
• Adults

Attention Deficit Hyperactivity Disorder, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Austria
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of APAC
• Latin America
• Argentina
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of MEA

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Attention Deficit Hyperactivity Disorder Market Insights

• 4.1. Attention Deficit Hyperactivity Disorder - Industry Snapshot
• 4.2. Attention Deficit Hyperactivity Disorder Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Prevalence of Attention Deficit Hyperactivity Disorder
    • 4.2.1.2. Easy Availability of Behavioural Rehabilitation Therapies
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Lack of Proper Reimbursement
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Attention Deficit Hyperactivity Disorder Market Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Attention Deficit Hyperactivity Disorder Market, by Drug Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
• 5.3. Stimulants
  • 5.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Stimulants, by Region, 2019-2032 (USD Million)
• 5.4. Non-stimulants
  • 5.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Non-stimulants, by Region, 2019-2032 (USD Million)

6. Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
• 6.3. Retail Pharmacy
  • 6.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Retail Pharmacy, by Region, 2019-2032 (USD Million)
• 6.4. Hospital Pharmacy
  • 6.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Million)

7. Global Attention Deficit Hyperactivity Disorder Market, by Demographics

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
• 7.3. Children (2 to 17 years of age)
  • 7.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Children (2 to 17 years of age), by Region, 2019-2032 (USD Million)
• 7.4. Adults
  • 7.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Adults, by Region, 2019-2032 (USD Million)

8. Global Attention Deficit Hyperactivity Disorder Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Attention Deficit Hyperactivity Disorder Market Assessment, By Geography, 2019-2032 (USD Million)
• 8.3. Attention Deficit Hyperactivity Disorder Market - North America
  • 8.3.1. North America: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
  • 8.3.2. North America: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
  • 8.3.3. North America: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.3.4. Attention Deficit Hyperactivity Disorder Market - U.S.
    • 8.3.4.1. U.S.: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.3.4.2. U.S.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.3.4.3. U.S.: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.3.5. Attention Deficit Hyperactivity Disorder Market - Canada
    • 8.3.5.1. Canada: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.3.5.2. Canada.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.3.5.3. Canada: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
• 8.4. Attention Deficit Hyperactivity Disorder Market - Europe
  • 8.4.1. Europe: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
  • 8.4.2. Europe.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
  • 8.4.3. Europe: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.4. Attention Deficit Hyperactivity Disorder Market - UK
    • 8.4.4.1. UK: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.4.2. UK.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.4.3. UK: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.5. Attention Deficit Hyperactivity Disorder Market - France
    • 8.4.5.1. France: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.5.2. France.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.5.3. France: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.6. Attention Deficit Hyperactivity Disorder Market - Germany
    • 8.4.6.1. Germany: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.6.2. Germany.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.6.3. Germany: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.7. Attention Deficit Hyperactivity Disorder Market - Italy
    • 8.4.7.1. Italy: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.7.2. Italy.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.7.3. Italy: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.8. Attention Deficit Hyperactivity Disorder Market - Spain
    • 8.4.8.1. Spain: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.8.2. Spain.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.8.3. Spain: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.9. Attention Deficit Hyperactivity Disorder Market - Netherlands
    • 8.4.9.1. Netherlands: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.9.2. Netherlands.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.9.3. Netherlands: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.10. Attention Deficit Hyperactivity Disorder Market - Russia
    • 8.4.10.1. Russia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.4.10.2. Russia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.4.10.3. Russia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
• 8.5. Attention Deficit Hyperactivity Disorder Market - Asia Pacific
  • 8.5.1. Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
  • 8.5.2. Asia Pacific.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
  • 8.5.3. Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.4. Attention Deficit Hyperactivity Disorder Market - China
    • 8.5.4.1. China: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.5.4.2. China.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.5.4.3. China: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.5. Attention Deficit Hyperactivity Disorder Market - India
    • 8.5.5.1. India: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.5.5.2. India.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.5.5.3. India: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.6. Attention Deficit Hyperactivity Disorder Market - Malaysia
    • 8.5.6.1. Malaysia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.5.6.2. Malaysia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.5.6.3. Malaysia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.7. Attention Deficit Hyperactivity Disorder Market - Japan
    • 8.5.7.1. Japan: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.5.7.2. Japan.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.5.7.3. Japan: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.8. Attention Deficit Hyperactivity Disorder Market - Indonesia
    • 8.5.8.1. Indonesia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.5.8.2. Indonesia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.5.8.3. Indonesia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.9. Attention Deficit Hyperactivity Disorder Market - South Korea
    • 8.5.9.1. South Korea: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.5.9.2. South Korea.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.5.9.3. South Korea: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
• 8.6. Attention Deficit Hyperactivity Disorder Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
  • 8.6.2. Middle East & Africa.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
  • 8.6.3. Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.6.4. Attention Deficit Hyperactivity Disorder Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.6.4.2. Saudi Arabia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.6.4.3. Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.6.5. Attention Deficit Hyperactivity Disorder Market - UAE
    • 8.6.5.1. UAE: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.6.5.2. UAE.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.6.5.3. UAE: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.6.6. Attention Deficit Hyperactivity Disorder Market - Israel
    • 8.6.6.1. Israel: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.6.6.2. Israel.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.6.6.3. Israel: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.6.7. Attention Deficit Hyperactivity Disorder Market - South Africa
    • 8.6.7.1. South Africa: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.6.7.2. South Africa.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.6.7.3. South Africa: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
• 8.7. Attention Deficit Hyperactivity Disorder Market - Latin America
  • 8.7.1. Latin America: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
  • 8.7.2. Latin America.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
  • 8.7.3. Latin America: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.7.4. Attention Deficit Hyperactivity Disorder Market - Mexico
    • 8.7.4.1. Mexico: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.7.4.2. Mexico.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.7.4.3. Mexico: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.7.5. Attention Deficit Hyperactivity Disorder Market - Brazil
    • 8.7.5.1. Brazil: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.7.5.2. Brazil.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.7.5.3. Brazil: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.7.6. Attention Deficit Hyperactivity Disorder Market - Argentina
    • 8.7.6.1. Argentina: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Million)
    • 8.7.6.2. Argentina.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Million)
    • 8.7.6.3. Argentina: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Million)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. ADVANZ PHARMA
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Amneal Pharmaceuticals LLC
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Aytu Biopharma, Inc
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Eli Lilly and Company
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Johnson & Johnson Services, Inc
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. Lupin
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Mallinckrodt
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Novartis AG
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Noven Pharmaceuticals, Inc
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Sun Pharmaceutical Industries Ltd
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. Supernus Pharmaceuticals, Inc
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Takeda Pharmaceutical Company Limited
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Torrent Pharmaceuticals Ltd
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. Tris Pharma, Inc
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development
• 10.15. Zevra Therapeutics
  • 10.15.1. Company Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Development